Rasnik Singh

Rasnik Singh

Auto-generated profile, based on publicly available information

Rasnik Singh

Department of Dermatology, Henry Ford Health System, Detroit, Michigan, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in JID Innovations
Verified
Journal Article
Open access
HCHsin-Wen Chang
Hsin-Wen Chang
DYDi Yan
Di Yan
RSRasnik Singh
Rasnik Singh
ABAudrey Bui
Audrey Bui
KLKristina Lee
Kristina Lee
WLWilson Liao
Wilson Liao
Psoriasis is a chronic, inflammatory skin disease that affects 2‒3% of the global population. Besides skin manifestations, patients with psoriasis have increased susceptibility to a number of comorbidities, including psoriatic arthritis, cardiovascular disease, and inflammatory bowel disease. To understand the systemic component of psoriasis pathogenesis, we performed a pilot study to examine the fecal metagenome, host colonic transcriptome, and host peripheral blood immune profiles of patients with psoriasis and healthy controls. Our study showed increased functional diversity in the gut microbiome of patients with psoriasis. In addition, we identified microbial species that preferentially associate with patients with psoriasis and which have been previously found to associate with other autoimmune diseases. Intriguingly, our data revealed three psoriasis subgroups that have distinct microbial and host features. Integrating these features revealed host‒microbe associations that are specific to psoriasis or particular psoriasis subgroups. Our findings provide insight into the factors that may affect the development of comorbidities in patients with psoriasis and may hold diagnostic potential for early identification of patients with psoriasis at risk for these comorbidities.

1 September 2016 in Journal of Psoriasis and Psoriatic Arthritis®
Verified
Journal Article
Open access
MNMio Nakamura
Mio Nakamura
TZTian Hao Zhu
Tian Hao Zhu
MAMichael Abrouk
Michael Abrouk
BFBenjamin Farahnik
Benjamin Farahnik
RSRasnik Singh
Rasnik Singh
TBTina Bhutani
Tina Bhutani
Introduction: Quality of life (QoL) is an important issue in psoriatic disease that should be included when assessing therapeutic efficacy of treatments. The objective of this study was to compare improvement in the dermatology life quality index (DLQI) between patients treated with adalimumab and ustekinumab. Methods: Analysis was based on two separate open-label 24-week clinical trials assessing DLQI and the Psoriasis Area and Severity Index (PASI) at four-week intervals in adult subjects with moderate to severe psoriasis treated with adalimumab or ustekinumab. Results: There were no statistically significant differences in the improvement in DLQI and PASI between the adalimumab and ustekinumab groups except at week 12 for DLQI and week 8 for PASI (ustekinumab > adalimumab). Discussion: Both adalimumab and ustekinumab improve QoL, but further research is necessary to determine specific factors that improve QoL and if one medication improves QoL more than another.